Expanded that inhibition of BCL-XL and MCL-1 can prevent the pathway focused screens could shed light on enduring development of resistance to BCL-2 inhibition in AML [48], and inhibition of the MAPK pathway with MEK inhibitors can prevent the development of resistance to EGFR inhibitors in colorectal cancer (CRC) [49]. The gene discussed is BCL2; the disease is acute myeloid leukemia.